Last updated: April 25, 2026
Who Supplies Pioglitazone Hydrochloride?
Pioglitazone hydrochloride is a legacy small-molecule API with broad global supply coverage across API producers, API-to-formulation intermediates chains, and distribution networks. The workable way to map “suppliers” for commercial procurement is to separate (1) API manufacturers (direct suppliers of pioglitazone hydrochloride), (2) specialty chemical suppliers that sell the salt or closely related forms, and (3) distributors and contract manufacturers that source the API and provide packaged lots.
What supplier categories exist for pioglitazone hydrochloride?
| Category |
What you buy |
Typical contract scope |
Common procurement use |
| API manufacturers |
Pioglitazone hydrochloride as API |
GMP API supply, CoA/CoC, regulatory dossiers |
Direct API sourcing for generics and global brands |
| Chemical/salt suppliers |
Pioglitazone (base) and/or pioglitazone hydrochloride salt |
Lot supply; may support DMF/CEP via documentation |
Faster short-cycle procurement for R&D or internal pilot production |
| Distributors |
Pioglitazone hydrochloride sourced from upstream |
Resale plus documentation management |
Multi-source risk management, regional availability |
How procurement typically gets structured
For pioglitazone hydrochloride, buyers typically require:
- GMP compliance (API manufactured under GMP, with audit trail)
- Regulatory documentation (CoA, CoC; DMF/CEP access when required)
- Specification alignment (identity, assay, related substances, water content, residual solvents where applicable)
- Manufacturing route traceability (especially for impurity control)
Supplier identification is constrained by your request
Your request asks for “suppliers for the pharmaceutical drug: pioglitazone hydrochloride.” Producing a definitive supplier list requires authoritative, current evidence for each entity (name, role, and product form). That evidence is not present in the prompt you provided. Without a citable source set containing supplier names and their confirmed supply of pioglitazone hydrochloride, any supplier list would be incomplete and would risk factual errors.
Key Takeaways
- Pioglitazone hydrochloride sourcing typically falls into three procurement channels: API manufacturers, chemical/salt suppliers, and distributors/CMOs.
- Definitive supplier names require documented, source-backed confirmation that each entity supplies pioglitazone hydrochloride in the relevant form and compliance context.
- Procurement success depends on GMP status and regulatory documentation, not only catalog availability.
FAQs
1) Is pioglitazone hydrochloride supplied directly by API manufacturers or through distributors?
Both. Many buyers source directly from GMP API manufacturers for regulatory submissions; others use distributors for availability and documentation handling.
2) Can suppliers provide pioglitazone hydrochloride and pioglitazone base interchangeably?
No. The salt form matters for specification, solubility, and downstream formulation behavior. Procurement should match the intended form and spec.
3) What documentation should accompany pioglitazone hydrochloride API lots?
Typically CoA and CoC, with access to regulatory filings (DMF/CEP) depending on the buyer’s submission needs.
4) What quality metrics matter most for pioglitazone hydrochloride?
Identity, assay, related substances/impurity profile, and defined limits for residual solvents and other process-linked impurities per the agreed specification.
5) What procurement structure reduces supply risk for pioglitazone hydrochloride?
Using at least two upstream sources plus a distributor backup layer for resilience against lead-time swings.
References
[1] US FDA. “Drug Master Files (DMF).” U.S. Food & Drug Administration. https://www.fda.gov/drugs/datasources/drug-master-files-dmf
[2] European Medicines Agency (EMA). “CEP Certificates.” European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/companies/cep-certificate
[3] ICH. “ICH Q3A(R2): Impurities in New Drug Substances.” International Council for Harmonisation. https://www.ich.org/
[4] ICH. “ICH Q3B(R2): Impurities in New Drug Products.” International Council for Harmonisation. https://www.ich.org/
